There are currently 178 clinical trials in Overland Park, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including Menorah Medical Center, University of Kansas Cancer Center-Overland Park, Saint Luke's South Hospital and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
NCT05130866
Recruiting
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: Sarah Cannon Cancer Institute - HCA Midwest, Overland Park, Kansas
Conditions: Neurofibromatosis Type 2
Register for Updates
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
NCT04781192
Recruiting
The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: University of Kansas Cancer Center - Overland Park, Overland Park, Kansas
Conditions: Advanced Biliary Tract Cancer
Register for Updates
Amyloidosis Incidence in High-Risk Cardiac Device Patients
NCT06186167
Recruiting
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a n... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Midwest Heart & Vascular Specialists, Overland Park, Kansas
Conditions: Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type
Register for Updates
ELUCIDATE FFRct Study
NCT06018194
Recruiting
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Midwest Heart and Vascular Specialists, Overland Park, Kansas
Conditions: Coronary Artery Disease
Register for Updates
Role of Novel ILR in the Management of PVCs
NCT06060548
Recruiting
This prospective, observational study is a single center clinical registry of patients referred for management of symptomatic or asymptomatic Premature Ventricular Contractions (PVCs). Subjects will be followed through 12 months. The study will enroll approximately 50 patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Kansas City Heart Rhythm Institute - Roe Clinic, Overland Park, Kansas +1 locations
Conditions: PVC - Premature Ventricular Contraction, Myocarditis
Register for Updates
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
NCT04992780
Recruiting
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas
Conditions: Non Small Cell Lung Cancer Stage
Register for Updates
PREHEVBRIO Pregnancy Outcomes Registry
NCT06097312
Recruiting
The registry is an observational surveillance program designed to recruit and encourage participation of women who were exposed to PREHEVBRIO® hepatitis B vaccine during pregnancy and to collect and analyze information related to post-exposure pregnancy and fetal and neonatal outcomes. The objective of the Registry is to monitor and evaluate all received reports of PREHEVBRIO® vaccine exposure within 28 days prior to conception or at any time during pregnancy and delivery, as well as maternal,... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
11/30/2023
Locations: ProPharma, Recruiting Nationwide, Overland Park, Kansas
Conditions: Vaccine Exposure During Pregnancy
Register for Updates
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
NCT04467801
Recruiting
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas
Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Register for Updates
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02302742
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2023
Locations: Menorah Medical Center, Overland Park, Kansas +2 locations
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Register for Updates
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas +1 locations
Conditions: Breast Cancer
Register for Updates